2017 Lash Group Announces Leadership Transition

November 16, 2017

Lash Group, a leader in patient support services and a part of AmerisourceBergen, recently announced that a new leader will soon take the reins. Tommy Bramley, PhD, will assume the role of President, Lash Group & Premier Source, effective November 13, 2017. In this position, he will have full strategic and operational responsibility for the businesses—leading the organization through the completion of its business transformation and continuing to grow the company around its patient-first philosophy of service delivery.


Bramley comes to Lash Group from Xcenda, a sister company within AmerisourceBergen’s broad portfolio of pharmaceutical commercialization solutions, where he most recently served as President for that organization. During his 16 years with the company, he was instrumental in expanding the organization’s scientific and commercial expertise to help life sciences companies prove value for products and maximize access for patients. Prior to becoming Xcenda’s President, Bramley held a host of leadership roles, including Senior Vice President, Scientific Consulting and Vice President, Payer & Outcomes Solutions.


“Combining deep relationships with the manufacturer community, a global mindset that has shaped Xcenda’s growth in Europe over the past two years and an abiding belief in the importance of corporate culture, Tommy’s leadership will propel Lash Group to sustained growth in an increasingly complex market,” said Jim Cleary, Group President, Global Commercialization Services & Animal Health for AmerisourceBergen.


At Lash Group, Bramley succeeds Tracy Foster, a 23-year veteran of the company and one of its co-founders. More than a company leader, Foster helped to shape the entire patient support services industry. She was essential in Lash Group’s development from its time as a start-up operation to become a company that now plays a crucial role in enabling millions of people each year to access their medications.


“It is important to me that Lash Group continues to transform, be the market leader, serve patients with excellence and integrity and be a great place to work,” said Foster. “I take great pride in what we’ve built and am optimistic that Lash Group will only grow better and stronger in the future.”


Lash Group’s track record purpose-driven excellence is not lost on Bramley. Indeed, it’s one of the aspects about the company that most excites him as he steps into the role.


“I have always been impressed by the passion and energy that Lash Group associates bring toward securing patients’ access to therapies,” said Bramley.  “Our associates’ dedication to patients has allowed Lash Group to achieve a commanding leadership position in the market—and, more importantly, has improved the lives of countless individuals. I am honored now to lead Lash Group, and I am committed to continuing the legacy of growth, innovation and dedication to improving patient lives.”